Lundberg Ellinor, Mattsson Fredrik, Gottlieb-Vedi Eivind, Lagergren Jesper
Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Ann Surg Oncol. 2025 May;32(5):3167-3174. doi: 10.1245/s10434-025-17007-3. Epub 2025 Feb 17.
The long-term survival after surgery for esophageal cancer has improved over the past few decades, but studies that assess recent survival trends are lacking.
This population-based cohort study included 2291 patients who underwent esophagectomy for esophageal cancer in Sweden between 2000 and 2020, with follow-up until 2024. Data came from medical records and national registries. Calendar time was analyzed as a continuous and categorized variable. The main outcome was all-cause 5-year mortality. Secondary outcomes were disease-specific 5-year mortality and 1-year all-cause mortality. Multivariable Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for age, sex, comorbidity, tumor histology, neoadjuvant therapy, hospital volume, and pathological tumor stage.
The study period witnessed increasing resection rates, centralization to fewer hospitals, and improving postoperative 5-year survival. When analyzing calendar time as a continuous variable, the adjusted HR for all-cause 5-year mortality was 0.97 (95% CI 0.95-0.98). In categorized analyses, the HRs decreased for each later time period and was 0.57 (95% CI 0.47-0.69) comparing the surgery period 2015-2020 with 2000-2004. The trends were similar for disease-specific 5-year mortality and all-cause 1-year mortality. In stratified analyses, patients with Charlson comorbidity score ≥2 had the strongest improvement in all-cause 5-year mortality (HR 0.45, 95% CI 0.30-0.69 comparing surgery in 2015-2020 with 2000-2004).
The recent 5-year survival has improved after surgery for esophageal cancer in Sweden. This improvement is not explained by lower surgery rates or selection of surgical candidates of younger age, fewer comorbidities, or earlier tumor stage.
在过去几十年中,食管癌手术后的长期生存率有所提高,但缺乏评估近期生存趋势的研究。
这项基于人群的队列研究纳入了2000年至2020年期间在瑞典接受食管癌食管切除术的2291例患者,随访至2024年。数据来自医疗记录和国家登记处。将日历时间作为连续变量和分类变量进行分析。主要结局是全因5年死亡率。次要结局是疾病特异性5年死亡率和全因1年死亡率。多变量Cox回归提供了风险比(HR)及95%置信区间(CI),并对年龄、性别、合并症、肿瘤组织学、新辅助治疗、医院规模和病理肿瘤分期进行了调整。
研究期间,切除率上升,手术集中在更少的医院,术后5年生存率提高。将日历时间作为连续变量分析时,全因5年死亡率的调整后HR为0.97(95%CI 0.95-0.98)。在分类分析中,每个较晚时间段的HR均降低,将2015-2020年手术期与2000-2004年进行比较时,HR为0.57(95%CI 0.47-0.69)。疾病特异性5年死亡率和全因1年死亡率的趋势相似。在分层分析中,Charlson合并症评分≥2的患者全因5年死亡率改善最为显著(将2015-2020年手术与2000-2004年进行比较时,HR为0.45,95%CI 0.3-0.69)。
瑞典近期食管癌手术后的5年生存率有所提高。手术率降低或选择年龄较小、合并症较少或肿瘤分期较早的手术候选者并不能解释这种改善。